Polymeric Eutectic System

Abstract:

The liquid eutectic system comprising 1:1 menthol:camphor was selected to use as solvent due to it was lowest viscosity. Both menthol and camphor used in this eutectic system have been reported for their many pharmaceutical used. Various polymers were tested for their solubility in this eutectic system. Eudragit® EPO showed the highest solubility. Eudragit® EPO was the one of biocompatible polymer which could dissolve in this eutectic system up to 40% w/w with no chemical interaction of each compound. Viscosity of this system showed the exponential curve as a function of polymer concentration but all concentration showed the newtonian rheology. The pH and surface tension were slightly affected by type and amount of polymers. The obtained polymeric eutectic mixture should control the drug release for pharmaceutical applications.

• Periodical: Advanced Materials Research (Volume 528)
• Pages: 180-183
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.528.180
• Online since: June 2012
• Authors: S. Tuntarawongsa, Thawatchai Phaechamud
• Keywords: Camphor, Eutectic Mixture, Menthol, Polymer

References

[1] AD Woolfson, RK Malcolm, K Campbell, DS Jones and JA Russell: J. Control. Rel. Vol. 67 (2000), pp.395-408.

[2] M Bi, SJ Hwang and KR Morris: Thermochim. Acta. Vol. 404 (2003), pp.213-26.

[3] PW Stott, AC Williams and BW Barry: J. Control. Rel. Vol. 50 (1998), p.297–308.

[4] PW Stott, AC Williams and BW Barry: Int. J. Pharm. Vol. 219 (2001), p.219: 161-76.

[5] CS Yong, YK Oh, SH Jung, J Rhee, H Kim, C Kim and H Choi: Eur. J. Pharm. Sci. Vol. 23 (2004), pp.347-353.

[6] M Lazerges, IB Rietveld, Y Corvis, R Céolin and P Espeau: Thermochim. Acta. Vol. 497 (2010), pp.124-8.

DOI: 10.1016/j.tca.2009.08.016

[7] CF Wahlgren and H Quiding: J. Am. Acad. Dermatol. Vol. 42 (1999), pp.584-9.

[8] S Nazzal, II Smalyukh, OD Lavrentovich and MA Khan: Int. J. Pharm. Vol. 235 (2002), pp.247-65.

[9] HG Morrison, CC Sun and S Neervannan: Int. J. Pharm. Vol. 378 (2010), pp.136-9.

[10] D Lindberg, M Revenga and M Widersten: J. Biotechol. Vol. 147 (2010), pp.169-71.

[11] RF Miller: US patent 20090247432, 2009 March 25.

[12] P Domınguez de Marıa and Z Maugeri: Curr. Opin. Chem. Biol. Vol. 15 (2010), pp.220-225.

[13] T Patel, Y Ishiuji and G Yosipovitch: J. Am. Acad. Dermatol. Vol. 57 (2007), pp.873-878.

[14] FA Al-Bayati: Ann. Clin. Microbiol. Antimicrob. (2009), 8: 20 doi: 10. 1186/1476-0711-8-20.

[15] CP Chang, TK Leung, SM Lin and CC Hsu: Colloids Surf., B. Vol. 50 (2006), p.136–140.

[16] Z Shunying, Y Yang, Y Huaidong, Y Yue and Z Guolin: J. Ethnopharmacol. Vol. 96 (2005), p.151–158.

[17] R Kotan, S Kordali, A Cakir, M Kesdek, Y Kaya and H Kilic: Biochem. Syst. Ecol. Vol. 36 (2008), pp.360-368.

DOI: 10.1016/j.bse.2007.12.003

[18] T Phaechamud, S Tuntarawongsa: CMICBA 2011. Chiang Mai University; 9-10 Aug 2011; Chiang Mai, Thailand (2011), p.135.

[19] Evonik Rӧhm GmbH Pharma Polymers: EUDRAGITÒ Acrylic Polymers for Solid Oral Dosage Forms. pp.1-14.

[20] JRV Flora, B Baker, D Wybenga, H Zhu, CM Aelion: Chemosphere. Vol. 70 (2008), p.1077–1084.

DOI: 10.1016/j.chemosphere.2007.07.060

[21] N Elgindy and W Samy: Int. J. Pharm. Vol. 376 (2009), pp.1-6.